RTP Mobile Logo

Regional Meetings 2017

Recently Approved and Emerging Strategies in the Management of Gastrointestinal Cancers: An Interactive Grand Rounds Series

Research To Practice is pleased to offer practicing oncologists and other allied healthcare professionals throughout the United States the opportunity to attend an educational activity focused on the management of Gastrointestinal Cancers. Each session in this regional series will include a blend of didactic minipresentations, video case presentations from clinicians in practice, interactive polling of the audience using keypad devices and follow-up discussion and audience Q&A.

If you are interested in hosting a session at your institution, please contact our Meeting Services department at Meetings@ResearchToPractice.com or call (800) 233-6153.

Event Details

Schedule of Events:

Friday, October 27, 2017
8:00 AM – 9:00 AM Education program


Faculty:
Johanna C Bendell, MD
SUNY Downstate Medical Center
Brooklyn, New York
Registration is open only to oncology professionals from this institution and invited guests.

Email us for more information.
There is no registration fee for these events. However, preregistration is advised, as seating is limited.

Agenda

This 1-hour session will include 4 topic modules focused on the current management of biologically defined subsets of gastrointestinal cancer and emerging research information on novel agents and strategies under active investigation. Each module will employ an identical format and include:

  • Audience Polling Using Keypad Devices
  • Display of Steering Committee Responses to Related Clinical Questions
  • Faculty Review of Select Data Sets
MODULE 1: Colorectal Cancer MODULE 2: Gastric Cancer MODULE 3: Hepatocellular Carcinoma MODULE 4: Integration of Novel Agents into the Treatment Algorithm

Each session will conclude with a 10-minute Q&A segment

STEERING COMMITTEE MEMBERS AND PARTICIPATING FACULTY

Tanios Bekaii-Saab, MD
Professor
Mayo Clinic College of Medicine and Science
Co-Leader, GI Cancer Program
Mayo Clinic Cancer Center
Senior Associate Consultant
Mayo Clinic Arizona
Scottsdale, Arizona

Johanna C Bendell, MD
Director, GI Oncology Research
Associate Director, Drug Development Unit
Sarah Cannon Research Institute
Nashville, Tennessee

Axel Grothey, MD
Professor of Oncology
Department of Medical Oncology
Mayo Clinic
Rochester, Minnesota

Howard S Hochster, MD
Associate Director (Clinical Research)
Yale Cancer Center
Professor of Medicine, Yale School of Medicine
New Haven, Connecticut

Heinz-Josef Lenz, MD
Professor of Medicine and Preventive Medicine
J Terrence Lanni Chair in Cancer Research
Co-Director, USC Center for Molecular
Pathways and Drug Discovery
Keck School of Medicine, University of
Southern California
Associate Director of Adult Oncology
Co-Director, Colorectal Center
Scientific Director, Cancer Genetics Unit
USC/Norris Comprehensive Cancer Center
Los Angeles, California
Bert H O’Neil, MD
Professor of Medicine
Director, Phase I and GI Malignancies Programs
Indiana University Simon Cancer Center
Indianapolis, Indiana

Philip A Philip, MD, PhD
Professor of Oncology and Medicine
Director of GI and Neuroendocrine Tumors
Vice President of Medical Affairs
Karmanos Cancer Institute
Wayne State University
Detroit, Michigan

Project Chair

Neil Love, MD
President
Research To Practice
Miami, Florida
 

CE Information

Target Audience:
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of gastrointestinal cancer.

Learning Objectives:

  • Appreciate the recent FDA approval of TAS-102, and develop an evidence-based approach to integrate this agent into the management of metastatic colorectal cancer.
  • Recognize the unique mechanism of action of, available clinical trial data with and clinical indications for the use of MM-398 for patients with treatment-refractory metastatic pancreatic cancer, and use this information to guide nonresearch treatment planning.
  • Consider available clinical research data documenting the efficacy of ramucirumab in metastatic colorectal and gastric or gastroesophageal junction cancers, and discern how this agent can be optimally integrated into clinical practice for patients with these diseases.
  • Educate patients with select gastrointestinal (GI) cancers regarding the potential side effects of recently approved agents, and provide preventive and emergent strategies to reduce or ameliorate these toxicities.
  • Develop an understanding of emerging Phase III efficacy data with and the potential clinical role of regorafenib in preparation for its potential introduction into the practical management of relapsed/refractory hepatocellular carcinoma.
  • Appraise the biologic rationale for and available clinical data with investigational anti-PD-1 and/or anti-PD-L1 antibodies in the treatment of select GI cancers.
  • Recall available and emerging data with other investigational agents currently in Phase III testing for various GI cancers, and, where applicable, refer eligible patients for trial participation or other expanded access programs.

CME Credit Form:
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statements:
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  

Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

Supporters:
These activities are supported by educational grants from Boston Biomedical Pharma Inc, Exelixis Inc, Lilly, Merck and Merrimack Pharmaceuticals Inc.

COCBC17/2

TARGET AUDIENCE
This activity is intended for medical oncologists, oncology fellows, oncology nurses and other healthcare providers involved in the treatment of breast cancer.

OVERVIEW OF ACTIVITY

COCBC17/1

TARGET AUDIENCE
This activity is intended for medical oncologists, oncology fellows, oncology nurses and other healthcare providers involved in the treatment of breast cancer.

OVERVIEW OF ACTIVITY

COCLymphoma16/7

TARGET AUDIENCE
This activity is intended for medical oncologists, radiation oncologists, nurses and other healthcare providers involved in the treatment of lymphomas and chronic lymphocytic leukemia (CLL).

OVERVIEW OF ACTIVITY

COCLymphoma16/6

TARGET AUDIENCE
This activity is intended for medical oncologists, radiation oncologists, nurses and other healthcare providers involved in the treatment of lymphomas and chronic lymphocytic leukemia (CLL).

OVERVIEW OF ACTIVITY

COCLymphoma16/5

TARGET AUDIENCE
This activity is intended for medical oncologists, radiation oncologists, nurses and other healthcare providers involved in the treatment of lymphomas and chronic lymphocytic leukemia (CLL).

OVERVIEW OF ACTIVITY

COCLymphoma16/4

TARGET AUDIENCE
This activity is intended for medical oncologists, radiation oncologists, nurses and other healthcare providers involved in the treatment of lymphomas and chronic lymphocytic leukemia (CLL).

OVERVIEW OF ACTIVITY

COCLymphoma16/3

TARGET AUDIENCE
This activity is intended for medical oncologists, radiation oncologists, nurses and other healthcare providers involved in the treatment of lymphomas and chronic lymphocytic leukemia (CLL).

OVERVIEW OF ACTIVITY

Consensus or Controversy: Clinical Investigators Provide Their Perspectives on Practical Issues and Research Questions in the Management of Non-Small Cell Lung Cancer

These audio proceedings from an Independent Satellite Symposium held at the 2012 ASCO Annual meeting offer the perspectives of 5 renowned international clinical investigators on a number of controversial management and research issues.

This content is available in a number of formats for listening on the go with a mobile device or at home on a computer.

COCLymphoma16/2

TARGET AUDIENCE
This activity is intended for medical oncologists, radiation oncologists, nurses and other healthcare providers involved in the treatment of lymphomas and chronic lymphocytic leukemia (CLL).

COCLymphoma16/1

TARGET AUDIENCE
This activity is intended for medical oncologists, radiation oncologists, nurses and other healthcare providers involved in the treatment of non-Hodgkin lymphoma (NHL).

BCU116/Video

TARGET AUDIENCE
This activity is intended for medical oncologists, hematologists-oncologists and other healthcare providers involved in the treatment of breast cancer (BC).

Regional Meetings 2017

Beyond the Guidelines: Clinical Investigators Provide Perspectives on Biomarker-Guided Decision-Making for Patients with Non-Small Cell Lung Cancer

Research To Practice is pleased to offer practicing oncologists and other allied healthcare professionals throughout the United States the opportunity to attend an educational activity focused on the management of non-small cell lung cancer (NSCLC). Each session in this regional series will include a blend of didactic minipresentations, video case presentations from clinicians in practice, interactive polling of the audience using keypad devices and follow-up discussion and audience Q&A.

If you are interested in hosting a session at your institution, please contact our Meeting Services department at Meetings@ResearchToPractice.com or call (800) 233-6153.

Event Details

Schedule of Events:

Tuesday, November 7, 2017
9:30 AM – 10:30 AM
Education program

Faculty:
Paul K Paik, MD
Allegheny General Hospital
Pittsburgh, Pennsylvania

Continental breakfast will be provided
Registration is open only to oncology professionals from this institution and invited guests.

Email us for more information.
There is no registration fee for these events. However, preregistration is advised, as seating is limited.

Agenda

Each 1-hour session will include 4 topic modules focused on the current management of biologically defined subsets of NSCLC and emerging research information on novel agents and strategies under active investigation. Each module will employ an identical format and include:

  • Audience Polling Using Keypad Devices
  • Display of Steering Committee Responses to Related Clinical Questions
  • Faculty Review of Select Data Sets
MODULE 1: Existing and Emerging Research Information with Immune Checkpoint Inhibitors MODULE 2: Evolving Clinical Strategies in the Management of EGFR Mutation-Positive NSCLC MODULE 3: Management of ALK- or ROS1-Positive NSCLC MODULE 4: BRAF, RET and Other Potentially Actionable Mutations

Each session will conclude with a 5-minute Q&A segment

STEERING COMMITTEE MEMBERS AND PARTICIPATING FACULTY

Julie R Brahmer, MD
Director, Thoracic Oncology Program
Interim Director, Johns Hopkins Kimmel Cancer Center at Bayview
Associate Professor of Oncology
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins School of Medicine
Baltimore, Maryland

Paul A Bunn Jr, MD
Distinguished Professor and James Dudley Chair
in Cancer Research
University of Colorado Cancer Center
Aurora, Colorado

D Ross Camidge, MD, PhD
Professor of Medicine/Oncology
Joyce Zeff Chair in Lung Cancer Research
University of Colorado Cancer Center
Aurora, Colorado

Alexander E Drilon, MD
Clinical Director
Developmental Therapeutics Clinic
Assistant Attending Physician
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

David E Gerber, MD
Associate Professor
Division of Hematology-Oncology
Associate Director for Clinical Research
Co-Leader, Experimental Therapeutics Program
Co-Director, Lung Disease Oriented Team
Harold C Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Dallas, Texas

Sarah B Goldberg, MD, MPH
Assistant Professor of Medicine
Medical Oncology
Yale Cancer Center
New Haven, Connecticut

Roy S Herbst, MD, PhD
Ensign Professor of Medicine (Oncology)
Professor of Pharmacology
Chief of Medical Oncology
Director, Thoracic Oncology Research Program
Associate Director for Translational Research
Yale Comprehensive Cancer Center
Yale School of Medicine
Smilow Cancer Hospital
New Haven, Connecticut

John V Heymach, MD, PhD
Professor and Chair
Thoracic/Head and Neck Medical Oncology
The University of Texas MD Anderson
Cancer Center
Houston, Texas

Leora Horn, MD, MSc
Associate Professor of Medicine
Clinical Director
Thoracic Oncology Research Program
Assistant Vice Chairman for Faculty Development
Vanderbilt University Medical Center
Nashville, Tennessee

Edward S Kim, MD
Professor and Chair
Department of Solid Tumor Oncology
and Investigational Therapeutics
Levine Cancer Institute
Carolinas HealthCare System
Charlotte, North Carolina

Mark G Kris, MD
William and Joy Ruane Chair in Thoracic Oncology
Attending Physician, Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Corey J Langer, MD
Director of Thoracic Oncology
Abramson Cancer Center
Professor of Medicine
Perelman School of Medicine
University of Pennsylvania
Vice Chair, Radiation Therapy Oncology Group
Philadelphia, Pennsylvania

Renato G Martins, MD, MPH
Stephen H Petersdorf Endowed Chair
in Cancer Care
Associate Medical Director
Solid Tumor Adult Oncology
Seattle Cancer Care Alliance
Professor
University of Washington
Seattle, Washington

Joel W Neal, MD, PhD
Assistant Professor of Medicine
Division of Oncology
Stanford Cancer Institute
Stanford University
Palo Alto, California

Paul K Paik, MD
Assistant Attending Physician
Clinical Director, Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Jyoti D Patel, MD
Professor of Medicine
The University of Chicago
Chicago, Illinois

Nathan A Pennell, MD, PhD
Associate Professor
Hematology and Medical Oncology
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Director, Cleveland Clinic Lung Cancer Medical Oncology Program
Cleveland, Ohio

Suresh S Ramalingam, MD
Professor of Hematology and Medical Oncology
Assistant Dean for Cancer Research
Emory University School of Medicine
Deputy Director, Winship Cancer Institute
Atlanta, Georgia

Lecia V Sequist, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Center for Thoracic Cancers
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Mark A Socinski, MD
Executive Medical Director
Member, Thoracic Oncology Program
Florida Hospital Cancer Institute
Orlando, Florida

David R Spigel, MD
Program Director, Lung Cancer Research
Sarah Cannon Research Institute
Nashville, Tennessee

Thomas E Stinchcombe, MD
Thoracic Oncology Program
Duke University Medical Center
Durham, North Carolina

Anne S Tsao, MD
Professor
Director, Mesothelioma Program
Director, Thoracic Chemo-Radiation Program
The University of Texas
MD Anderson Cancer Center
Department of Thoracic/Head and
Neck Medical Oncology
Houston, Texas

Everett E Vokes, MD
John E Ultmann Professor
Chairman, Department of Medicine
Physician-in-Chief
University of Chicago Medicine and Biological Sciences
Chicago, Illinois

Heather Wakelee, MD
Associate Professor of Medicine
Division of Oncology
Stanford University School of Medicine
Stanford Cancer Institute
Stanford, California

Project Chair

Neil Love, MD
President
Research To Practice
Miami, Florida
 

CE Information

Target Audience:
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of NSCLC.

Learning Objectives:

  • Evaluate existing guideline recommendations regarding the indications and optimal testing platform for mutational analysis for patients with metastatic NSCLC, and use this information to implement a comprehensive approach to genomic assessment.
  • Use mutation status, clinical characteristics and tumor histology to appropriately prioritize front-line and subsequent treatment approaches for patients with metastatic NSCLC.
  • Employ an understanding of personalized medicine to individualize the use of available EGFR inhibitors in the long-term management of EGFR mutation-positive NSCLC, and discern how novel EGFR tyrosine kinase inhibitors can be optimally administered to patients with progressive EGFR mutation-positive disease.
  • Communicate the efficacy and safety of approved and other emerging ALK inhibitors to appropriate patients with NSCLC, considering the predictive utility of ALK mutation testing.
  • Recall existing and emerging research information demonstrating the efficacy and safety of anti-PD-1/PD-L1 antibodies for patients with squamous and nonsquamous metastatic NSCLC, and use this information to guide treatment planning.
  • Recall the design of ongoing clinical trials evaluating novel investigational agents in NSCLC, and counsel appropriately selected patients about availability and participation.

CME Credit Form:
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement:
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

Supporters:
These activities are supported by educational grants from Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Genentech BioOncology and Merck.

GICancers16/Roundtable

TARGET AUDIENCE
This activity is intended for medical oncologists, hematology-oncology fellows, surgeons and other healthcare providers involved in the treatment of gastrointestinal (GI) cancers.

LCU116/Video

TARGET AUDIENCE
This activity is intended for medical oncologists, radiation oncologists and other healthcare providers involved in the treatment of lung cancer.